| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000328021 |
| P698 | PubMed publication ID | 21597288 |
| P50 | author | Yoon Jae Kim | Q40606527 |
| Seungmin Bang | Q59507648 | ||
| P2093 | author name string | Seung Woo Park | |
| Jeong Youp Park | |||
| Moon Jae Chung | |||
| Si Young Song | |||
| Jae Bock Chung | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. | Q33371325 | ||
| Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. | Q33373098 | ||
| Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer | Q33375714 | ||
| Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. | Q33379860 | ||
| Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer | Q33381385 | ||
| Gemcitabine, irinotecan and celecoxib in patients with biliary cancer | Q33382984 | ||
| Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study | Q33383423 | ||
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial | Q33620083 | ||
| Cholangiocarcinoma. | Q33990595 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate | Q34550827 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
| Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? | Q36610851 | ||
| Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial | Q36614800 | ||
| Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines | Q36620291 | ||
| Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines | Q40662997 | ||
| Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. | Q43020287 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma | Q46145907 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research | Q46453554 | ||
| Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. | Q46716472 | ||
| Acting on imperfect evidence: How much regret are we ready to accept? | Q50958186 | ||
| P433 | issue | 3 | |
| P921 | main subject | irinotecan | Q412197 |
| chemotherapy | Q974135 | ||
| ??? | Q18556397 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 236-243 | |
| P577 | publication date | 2011-05-19 | |
| P1433 | published in | Chemotherapy | Q2440355 |
| P1476 | title | Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer | |
| P478 | volume | 57 |
Search more.